February 9, 2017 06:02 AM EST

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII

John Carroll

Editor & Founder

Acorda’s $525 million gamble on a Phase III Parkinson’s drug has paid off. The biotech $ACOR announced early Thursday that the late-stage study of an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Acor­da preps FDA fil­ing af­ter Parkin­son’s drug hits the pri­ma­ry end­point in PhI­II

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII